Literature DB >> 7648235

Development and preliminary assessment of a simple measure of overall status in rheumatoid arthritis (OSRA) for routine clinical use.

D P Symmons1, A B Hassell, K A Gunatillaka, P J Jones, J Schollum, P T Dawes.   

Abstract

We describe the development and initial assessment of a simple measure of overall status in rheumatoid arthritis (OSRA) for use in the routine clinical setting. The measure is constructed in four parts: demographic details, activity score, damage score and treatment category. It requires no laboratory tests and uses details collected routinely during a clinic visit. It was validated in a series of 488 patients. The measure proved acceptable and demonstrated face, content, construct and discriminant validity. OSRA will be useful as an audit tool in the serial follow-up of RA patients and in describing the characteristics of a population of such patients.

Entities:  

Mesh:

Year:  1995        PMID: 7648235

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  4 in total

1.  The rheumatoid arthritis articular damage score: first steps in developing a clinical index of long term damage in RA.

Authors:  T R Zijlstra; H J Bernelot Moens; M A S Bukhari
Journal:  Ann Rheum Dis       Date:  2002-01       Impact factor: 19.103

2.  Tumour necrosis factor-alpha, interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis.

Authors:  Tânia Silvia Fröde; Patrícia Tenconi; Marilei Reynaud Debiasi; Yara Santos Medeiros
Journal:  Mediators Inflamm       Date:  2002-12       Impact factor: 4.711

3.  An initial investigation into endothelial CC chemokine expression in the human rheumatoid synovium.

Authors:  Lisa Rump; Derek L Mattey; Oksana Kehoe; Jim Middleton
Journal:  Cytokine       Date:  2017-09       Impact factor: 3.861

4.  The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28.

Authors:  Masayo Sato; Sebastian Schneeweiss; Richard Scranton; Jeffrey N Katz; Michael E Weinblatt; Jerry Avorn; Gladys Ting; Nancy A Shadick; Daniel H Solomon
Journal:  Arthritis Res Ther       Date:  2006-03-14       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.